This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| IST-3 | |
|---|---|
| Name | IST-3 |
| Full name | International Stroke Trial 3 |
| Acronym | IST-3 |
| Start date | 2000 |
| Completion date | 2012 |
| Locations | United Kingdom, Europe |
| Principal investigator | Peter Sandercock |
| Funding | Medical Research Council, British Heart Foundation |
IST-3 The International Stroke Trial 3 was a multicentre randomized clinical trial testing the efficacy of intravenous thrombolysis in acute ischemic stroke. The trial involved academic hospitals and research networks across Europe and the United Kingdom, coordinated by leading stroke investigators and trialists. It influenced clinical guidelines from organizations such as the National Institute for Health and Care Excellence and the European Stroke Organisation.
The trial arose amid debates involving landmark studies like ECASS III, NINDS t-PA Trial, PROACT II and guidance from World Health Organization, Royal College of Physicians, American Heart Association and European Stroke Organisation. Lead investigators drew on prior randomized evidence from centers associated with University of Glasgow, University of Edinburgh, Oxford University Hospitals, John Radcliffe Hospital and networks including Stroke Unit Trialists' Collaboration. Funding and oversight intersected with agencies such as the Medical Research Council (United Kingdom), British Heart Foundation and ethics frameworks influenced by the Declaration of Helsinki and regulatory bodies like the Medicines and Healthcare products Regulatory Agency.
IST-3 used a pragmatic, randomized, open-label, blinded endpoint (PROBE) design influenced by methodology from trials at NINDS, ECASS, and SITS-MOST. The protocol and statistical analysis plan were developed with input from biostatisticians affiliated with University of Oxford, University of Edinburgh, Imperial College London and London School of Hygiene & Tropical Medicine. Data monitoring was overseen by an independent data monitoring committee chaired by clinicians linked to Royal Infirmary of Edinburgh and methodologists from Clinical Trials Unit, University of Edinburgh and Clinical Trials Unit, University of Oxford.
Participants were adults presenting with acute ischemic stroke to hospitals across the United Kingdom, Poland, Spain, Italy, France, Netherlands, Germany and other European centres including tertiary referral centres such as Addenbrooke's Hospital, St Thomas' Hospital and Royal Victoria Infirmary. Inclusion and exclusion criteria mirrored practice in major stroke centres associated with Stroke Association (United Kingdom), and recruitment involved stroke physicians trained in protocols from European Stroke Organisation workshops and courses endorsed by Royal College of Physicians faculty.
The active intervention was intravenous recombinant tissue plasminogen activator administered according to dosing regimens used in trials at NINDS and ECASS III, with control subjects receiving standard care at centres following protocols from National Institute for Health and Care Excellence and local stroke unit pathways from institutions like King's College Hospital and Guy's and St Thomas' NHS Foundation Trust.
Primary outcome measures included functional status measured by the Oxford Handicap Scale and modified Rankin Scale at 6 months, with analysis methods informed by statistical practices from Cochrane Collaboration systematic reviews and consensus statements from the CONSORT group. Secondary outcomes included mortality, symptomatic intracerebral hemorrhage defined per criteria used in ECASS III and health economic endpoints relevant to commissioners such as National Health Service (England). Analyses employed intention-to-treat frameworks and adjusted regression models developed with statisticians from University of Oxford and London School of Hygiene & Tropical Medicine.
The trial enrolled thousands of patients and reported effect estimates for functional outcomes, mortality and hemorrhagic complications consistent with a modest net benefit in selected patients, echoing findings from earlier trials like NINDS t-PA Trial while extending evidence to older age groups and later time windows similar to discussions in ECASS III. Results were published in major journals and presented at conferences hosted by European Stroke Organisation, American Stroke Association, British Association of Stroke Physicians and academic meetings at Royal College of Physicians.
IST-3 informed revisions to clinical guidance by bodies including National Institute for Health and Care Excellence, European Stroke Organisation and influenced practice at stroke centres such as Addenbrooke's Hospital and Oxford University Hospitals. The findings prompted debates within committees of British Medical Association and influenced training curricula endorsed by Royal College of Physicians and research agendas at funding bodies like the Medical Research Council (United Kingdom) and British Heart Foundation.
Critics compared IST-3 methodology and interpretation with trials including ECASS III, NINDS t-PA Trial, SITS-MOST and raised issues about open-label design, selection bias across participating centres such as Royal Infirmary of Edinburgh and John Radcliffe Hospital, and the generalizability to health systems outside the United Kingdom. Debates played out in editorials in journals associated with BMJ Publishing Group, The Lancet, New England Journal of Medicine and at symposia convened by European Stroke Organisation and American Heart Association.
Category:Clinical trials